Unleashing Chk1 in cancer therapy

Cell Cycle

Volumn 10, Issue 13, 2011, Pages 2121-2128

  Carrassa, Laura ^a   Damia, Giovanna ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Cancer therapy; Cell cycle regulation; Chk1; DNA damage checkpoints; Genomic stability; Synthetic lethality

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ARRY 575; AZD 7762; BRCA1 PROTEIN; CASPASE 3; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHR 124; CISPLATIN; CYTARABINE; DOCETAXEL; GEMCITABINE; HISTONE H2AX; IC 83; IRINOTECAN; LY 2603618; PF 477736; REPLICATION FACTOR A; ROSCOVITINE; SAR 020106; SCH 900776; SINGLE STRANDED DNA; TOPOTECAN; UNCLASSIFIED DRUG; XL 844;

ACUTE LEUKEMIA; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER THERAPY; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; COMPETITIVE INHIBITION; DIARRHEA; DNA DAMAGE; DNA REPLICATION; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO DEVELOPMENT; FANCONI ANEMIA; FATIGUE; GENOMIC INSTABILITY; HEART ATRIUM FIBRILLATION; HELA CELL; HUMAN; IONIZING RADIATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MICROSATELLITE INSTABILITY; MITOSIS; MITOSIS SPINDLE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

EID: 79959978644     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.13.16398     Document Type: Review

References (87)

1. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547-66.
2. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: New selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008; 17:1331-40.
3. Poehlmann A, Roessner A. Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract 206:591-601.
4. Walworth N, Davey S, Beach D. Fission yeast chk1 protein kinase links the rad checkpoint pathway to cdc2. Nature 1993; 363:368-71. (Pubitemid 23161536)
5. Stracker TH, Usui T, Petrini JH. Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 2009; 8:1047-54.
6. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59.
7. Zachos G, Rainey MD, Gillespie DA. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 2003; 22:713-23. (Pubitemid 36193615)
8. Carrassa L, Broggini M, Erba E, Damia G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: Differential activity in cells expressing or not p53. Cell Cycle 2004; 3:1177-81. (Pubitemid 40268636)
9. 2 DNA damage checkpoint. Mol Cancer Ther 2003; 2:543-8.
10. Lam MH, Rosen JM. Chk1 versus Cdc25: Chking one's levels of cellular proliferation. Cell Cycle 2004; 3:1355-7. (Pubitemid 40310665)
11. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets and DNA breakage. Mol Cell Biol 2005; 25:3553-62. (Pubitemid 40559562)
12. Carrassa L, Sanchez Y, Erba E, Damia G. U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint. J Cell Mol Med 2009; 13:1565-76.
13. Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29:4007-17.
14. Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, et al. Activation of mammalian Chk1 during DNA replication arrest: A role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154:913-23. (Pubitemid 34286172)
15. Maya-Mendoza A, Petermann E, Gillespie DA, Caldecott KW, Jackson DA. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 2007; 26:2719-31. (Pubitemid 46884282)
16. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26:3319-26.
17. Wilsker D, Petermann E, Helleday T, Bunz F. Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control. Proc Natl Acad Sci USA 2008; 105:20752-7.
18. Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA 107:16090-5.
19. Tang J, Erikson RL, Liu X. Checkpoint kinase 1 (Chk1) is required for mitotic progression through negative regulation of polo-like kinase 1 (Plk1). Proc Natl Acad Sci USA 2006; 103:11964-9.
20. Kramer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA, et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 2004; 6:884-91. (Pubitemid 39207253)
21. Jackman M, Lindon C, Nigg EA, Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003; 5:143-8. (Pubitemid 36204196)
22. 2/M transition. J Biol Chem 2009; 284:34223-30.
23. Peddibhotla S, Lam MH, Gonzalez-Rimbau M, Rosen JM. The DNA-damage effector checkpoint kinase1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci USA 2009; 106:5159-64.
24. Solyom S, Pylkas K, Winqvist R. Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families. Fam Cancer 9:537-40.
25. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277:1497-501. (Pubitemid 27449236)
26. Bertoni F, Codegoni AM, Furlan D, Tibiletti MG, Capella C, Broggini M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999; 26:176-80. (Pubitemid 29416444)
27. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002; 62:4095-9. (Pubitemid 34791080)
28. Furlan D, Casati B, Cerutti R, Facco C, Terracciano L, Capella C, et al. Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J Pathol 2002; 197:603-9.
29. Haruki N, Saito H, Tatematsu Y, Konishi H, Harano T, Masuda A, et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res 2000; 60:4689-92.
30. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, et al. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 2009; 15:6327-40.
31. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor/HER-2 breast carcinomas. Cancer Res 2007; 67:6574-81. (Pubitemid 47105501)
32. Leung-Pineda V, Huh J, Piwnica-Worms H. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res 2009; 69:2630-7.
33. Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, et al. The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell 2009; 35:442-53.
34. Merry C, Fu K, Wang J, Yeh IJ, Zhang Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 9:279-83.
35. Bartek J, Lukas J. DNA damage checkpoints: From initiation to recovery or adaptation. Curr Opin Cell Biol 2007; 19:238-45. (Pubitemid 46386406)
36. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9:297-308. (Pubitemid 351430844)
37. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408:433-9.
38. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000; 288:1425-9. (Pubitemid 30366329)
39. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H. Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997; 277:1501-5. (Pubitemid 27449237)
40. 2 checkpoints. Proc Natl Acad Sci USA 2002; 99:14795-800.
41. Gottifredi V, Prives C. The S phase checkpoint: When the crowd meets at the fork. Semin Cell Dev Biol 2005; 16:355-68.
42. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006; 8:37-45. (Pubitemid 43064795)
43. Zachos G, Black EJ, Walker M, Scott MT, Vagnarelli P, Earnshaw WC, et al. Chk1 is required for spindle checkpoint function. Dev Cell 2007; 12:247-60. (Pubitemid 46193970)
44. Suijkerbuijk SJ, Kops GJ. Preventing aneuploidy: The contribution of mitotic checkpoint proteins. Biochim Biophys Acta 2008; 1786:24-31.
45. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5:773-85. (Pubitemid 41400777)
46. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195-201. (Pubitemid 40268135)
47. Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008; 27:3977-85. (Pubitemid 351913634)
48. Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, Ding J. Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther 2008; 7:1440-9.
49. Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, D'Andrea AD. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 2007; 27:3098-108. (Pubitemid 46581321)
50. Rodriguez R, Meuth M. Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress. Mol Biol Cell 2006; 17:402-12. (Pubitemid 43049492)
51. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2 and caspase-3. Cell 2008; 133:864-77. (Pubitemid 351715394)
52. Myers K, Gagou ME, Zuazua-Villar P, Rodriguez R, Meuth M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet 2009; 5:1000324.
53. Aparicio T, Guillou E, Coloma J, Montoya G, Mendez J. The human GINS complex associates with Cdc45 and MCM and is essential for DNA replication. Nucleic Acids Res 2009; 37:2087-95.
54. Bauerschmidt C, Pollok S, Kremmer E, Nasheuer HP, Grosse F. Interactions of human Cdc45 with the Mcm2-7 complex, the GINS complex and DNA polymerases delta and epsilon during S phase. Genes Cells 2007; 12:745-58. (Pubitemid 46952548)
55. Rodriguez R, Gagou ME, Meuth M. Apoptosis induced by replication inhibitors in Chk1-depleted cells is dependent upon the helicase cofactor Cdc45. Cell Death Differ 2008; 15:889-98. (Pubitemid 351524431)
56. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008; 132:221-32. (Pubitemid 351172429)
57. Carrassa L, Montelatici E, Lazzari L, Zangrossi S, Simone M, Broggini M, et al. Role of Chk1 in the differentiation program of hematopoietic stem cells. Cell Mol Life Sci 67:1713-22.
58. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-83.
59. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 17:88-96.
60. Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggini M, Damia G. Checkpoint kinase 1 downregulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res 2008; 14:5131-41.
61. Dixon H, Norbury CJ. Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 2002; 1:362-8.
62. Blagosklonny MV, Dixon SC, Robey R, Figg WD. Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines. Int J Oncol 2001; 18:697-704.
63. 2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 2002; 21:6249-54.
64. Zenvirt S, Kravchenko-Balasha N, Levitzki A. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents. Oncogene 29:6149-59.
65. Converso A, Hartingh T, Garbaccio RM, Tasber E, Rickert K, Fraley ME, et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. Bioorg Med Chem Lett 2009; 19:1240-4.
66. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007; 13:591-602. (Pubitemid 46225366)
67. Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 9:89-100.
68. th International Symposium on Targeted Anticancer therapies. Paris: Ann Oncolo 2011; 22:3.
69. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38. (Pubitemid 44547703)
70. 2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-81.
71. McArthur GA, Raleigh J, Blasina A, Cullinane C, Dorow D, Conus N, et al. Imaging with FLT-PET demonstrates that PF-477736, an inhibitor of CHK1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts. ASCO Meeting Abstracts 2006; 24:3045.
72. Brega N, McArthur GA, Britten C, Wong SG, Wang E, Wilner KD, et al. Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase. ASCO Meeting Abstracts 28:3062.
73. Daud A, Springett GM, Mendelson DS, Munster PN, Goldman JW, Strosberg JR, et al. A phase I doseescalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors. ASCO Meeting Abstracts 28:3064.
74. st International Symposium on Medicinal Chemistry 2010.
75. th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Geneva, Switzerland 2008.
76. Exelixis Inc., starts three new Phase I Clinical Trilas for novel compounds: XL844, XL184 and XL784 2005.
77. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-98.
78. Canaani D. Methodological approaches in application of synthetic lethality screening towards anticancer therapy. Br J Cancer 2009; 100:1213-8.
79. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7. (Pubitemid 40559005)
80. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34.
81. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008; 27:1368-77. (Pubitemid 351655175)
82. Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 2009; 8:3112-9.
83. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009; 8:24.
84. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: Recent progress. Blood 2006; 107:4223-33. (Pubitemid 43801344)
85. van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, et al. Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004; 165:651-7. (Pubitemid 38971394)
86. Lim SL, Smith P, Syed N, Coens C, Wong H, van der Burg M, et al. Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer 2008; 98:1452-6. (Pubitemid 351543586)
87. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 70:9693-702.